POST-discharge thromboprophylaxis in patients with COVID-19: a single-center experience

Article Pharmacology & Pharmacy

Evaluation of the Clinical Impact of Thromboprophylaxis in Patients With COVID-19 Following Hospital Discharge

Lindsay A. Courtney et al.

Summary: This study evaluated the incidence of thromboembolic and bleeding events post-discharge among COVID-19 patients, as well as the role of thromboprophylaxis. The results suggest that post-discharge extended prophylaxis may be beneficial for select COVID-19 patients while considering the risk of bleeding.

ANNALS OF PHARMACOTHERAPY (2022)

Add to Collection

Article Medicine, General & Internal

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial

Eduardo Ramacciotti et al.

Summary: This study investigated the efficacy of rivaroxaban thromboprophylaxis for 35 days in patients discharged after hospitalisation due to COVID-19. The results showed that this treatment significantly reduced the incidence of venous thromboembolism, with no major bleeding events reported.

LANCET (2022)

Add to Collection

Article Cell Biology

Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19

Elena Campello et al.

Summary: The study found that extracellular vesicles (EVs) from cells involved in COVID-19-associated coagulopathy increased in COVID-19 patients at admission and discharge, with a decrease in endothelium-derived EVs 30 days post-discharge, while platelet- and leukocyte-derived EVs further increased.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Add to Collection

Article Hematology

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients

Adam Cuker et al.

Summary: This guideline from ASH provides evidence-based recommendations for the use of anticoagulation in COVID-19 patients, emphasizing the need for individualized assessment of thrombosis and bleeding risk. The guideline suggests therapeutic-intensity anticoagulation over prophylactic-intensity for patients with COVID-19-related acute illness who do not have suspected or confirmed VTE.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

ISTH guidelines for antithrombotic treatment in COVID-19

Sam Schulman et al.

Summary: Antithrombotic agents, particularly heparins, are recommended for patients with COVID-19 to reduce thromboembolism risk. The optimal dosing and timing of these treatments, as well as the benefits of other antithrombotic agents, are still unclear. A panel of experts developed 12 recommendations based on high- to moderate-quality evidence, including the use of prophylactic or therapeutic dose heparin for different patient groups. Additional weak recommendations were made for the use of sulodexide, adding antiplatelet agents, and prophylactic rivaroxaban in select patients. Future updates will incorporate new evidence and may modify these recommendations.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Review Hematology

Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients

Alex C. Spyropoulos

Summary: Extended post-discharge thromboprophylaxis can reduce the risk of venous and arterial thromboembolic events in hospitalized COVID-19 patients. Patients with cardiovascular risk factors, advanced age, ICU stay, or high-risk scores should receive extended thromboprophylaxis after discharge, specifically with rivaroxaban 10 mg daily for 35 days.

EXPERT REVIEW OF HEMATOLOGY (2022)

Add to Collection

Article Medical Laboratory Technology

Thrombin generation in patients with COVID-19 with and without thromboprophylaxis

Elena Campello et al.

Summary: COVID-19 patients showed increased thrombin generation at diagnosis. Standard thromboprophylaxis reduced thrombin generation to levels of healthy controls. Intermediate sub-therapeutic thromboprophylaxis more effectively inhibited thrombin generation by decreasing ETP with TM.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2021)

Add to Collection

Article Hematology

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry

Dimitrios Giannis et al.

Summary: Thromboembolic events and mortality from subclinical thrombotic events frequently occur in COVID-19 inpatients. Postdischarge VTE, ATE, and ACM are common, with advanced age and cardiovascular risk factors increasing the risk. Postdischarge anticoagulation can significantly reduce the risk by 46%.

BLOOD (2021)

Add to Collection

Review Hematology